Short Communication Open Access
Volume 1 | Issue 4 | DOI: https://doi.org/10.33696/Neurol.1.023
Can ECT Improve the Motor Symptoms of a Neurological Disease? A Case of Dopa-Responsive Dystonia
Clement Guillet1,*
- 1La Chartreuse Psychiatric Hospital, Depression Unit, Dijon, France
Corresponding Author
Clement Guillet, clementguillet@hotmail.com
Received Date: October 23, 2020
Accepted Date: December 01, 2020
Guillet C. Can ECT Improve the Motor Symptoms of a Neurological Disease? A Case of Dopa-Responsive Dystonia. J Exp Neurol. 2020;1(4): 148-151.
Copyright: © 2020 Guillet C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
A 28-year-old woman suffering from a rare genetic disorder, autosomal recessive dopa-responsive dystonia, presented with drugresistant depression. The motor symptoms of her condition were significantly improved for several months after treatment with electroconvulsive therapy (ECT). This raises the question of whether ECT could be used to treat the motor symptoms of neurological diseases.
Recommended Articles
To Stick or Not to Stick? Scalp and Intracranial EEG Evaluation Both Help Achieve Good Surgical and Neuropsychiatric Outcomes in Epilepsy Surgery up to 20 Years Post-Surgery
Epilepsy has a worldwide prevalence of about 50 million [1]. Seizure medications provide adequate control in two thirds of these patients but about a third are refractory to multiple medications and need surgery or other treatments [2].
Integrating Neurology and Psychiatry throughout Educational Curricula for Healthcare Professionals
We recently reviewed the scientific literature linking dopamine agonist pharmacotherapy for neurological disorders to the development of impulsive and compulsive spectrum disorders (ICSDs).
Is Cellular Senescence of Dopaminergic Neurons the Cause of Local Inflammation in the Midbrain Observed in Parkinson’s Disease?
Current research investigating the pathomechanisms of neurodegenerative disorders of the central nervous system (CNS), such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), or Parkinson’s disease (PD), led to the understanding that these diseases have to be seen in the context of immune responses [1]. In other words,
Phosphoinositide-Specific Phospholipases C in Psychiatric Diseases and Suicide
Mood disorders represent a major medical need requiring chronic treatment. About one million people die by suicide worldwide each year, both as a consequence of major depression or not. Multiple deficits, including cell atrophy and loss, were described in the brains of mood disorders affected patients and in experimental animal models. Numerous changes in gene expression and activity were described in limbic and cortical brain regions.
Why Can Modulation of α6-Containing GABAA Receptors Reduce the Symptoms of Multiple Neuropsychiatric Disorders?
α6-containing GABAA receptors (α6GABAARs) are strongly expressed in cerebellar granule cells, where they mediate a correctly timed and precise coordination of all muscle groups that execute behavior and protect the brain from information overflow. Recently, it was demonstrated that positive modulators with a high selectivity for α6GABAARs (α6-modulators) can reduce the symptoms of multiple neuropsychiatric disorders in respective animal models to an extent comparable with established clinical therapeutics.